These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1165 related articles for article (PubMed ID: 1342779)

  • 1. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
    Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
    Lu HR; Lijnen HR; Stassen JM; Collen D
    Blood; 1991 Jul; 78(1):125-31. PubMed ID: 1906351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
    Spriggs DJ; Stassen JM; Hashimoto Y; Collen D
    Blood; 1989 Apr; 73(5):1207-12. PubMed ID: 2495034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary thrombolysis with K1K2Pu, a chimeric tissue-type and urokinase-type plasminogen activator: a feasibility study in six patients with acute myocardial infarction.
    Van de Werf F; Lijnen HR; Collen D
    Coron Artery Dis; 1993 Oct; 4(10):929-33. PubMed ID: 8269200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
    Collen D; Nelles L; De Cock F; Lemmens G; Van Coetsem T; Demarsin E; Lijnen HR
    Thromb Res; 1992 Feb; 65(3):421-38. PubMed ID: 1631805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic effects of thrombolytic agents in a platelet-rich femoral vein thrombosis model in the hamster.
    Stassen JM; Nyström A; Hoylaerts M; Collen D
    Circulation; 1995 Mar; 91(5):1330-5. PubMed ID: 7867170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
    Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
    Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
    Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
    Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
    Holvoet P; Dewerchin M; Stassen JM; Lijnen HR; Tollenaere T; Gaffney PJ; Collen D
    Circulation; 1993 Mar; 87(3):1007-16. PubMed ID: 8443877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of recombinant pro-urokinase given by intraarterial versus intravenous routes of administration in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Wegner CD; Cox BF
    Thromb Haemost; 1999 Feb; 81(2):301-5. PubMed ID: 10064010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons.
    Imura Y; Stassen JM; Kurokawa T; Iwasa S; Lijnen HR; Collen D
    Blood; 1992 May; 79(9):2322-9. PubMed ID: 1571545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.
    Holvoet P; Laroche Y; Stassen JM; Lijnen HR; Van Hoef B; De Cock F; Van Houtven A; Gansemans Y; Matthyssens G; Collen D
    Blood; 1993 Feb; 81(3):696-703. PubMed ID: 8427962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
    Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
    Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
    Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
    Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Henkin J
    Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.